You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Related products

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »
 

Anti-NFkB p100 / p52 antibody (ab31432)

CodeSizePriceAbpointsAvailability
    
 
  • -
  •   
  •   
  •   
  •  
  •   
  •   
Updating...

Overview

Product name

Anti-NFkB p100 / p52 antibody
See all NFkB p100 / p52 products (11) ...

Description

Rabbit polyclonal to NFkB p100 / p52

Specificity

This antibody detects sites on p100 only. Sometimes there is a 52kDa band on WB; this is not p52. There is a cleavage site on the NFKB2 (Swiss-Prot No.: Q00653). The cleavage site is between 454 and 455 (cleavage when cotranslationally processed). The antibody can interact with the C-half sometimes. The MW. of C-half is near 52Kd.

Tested applications

ELISA, WB, IP, IHC-Pmore details

Cross reactivity

Reacts with

Mouse, Rat, Human

Immunogen

Synthetic non phosphopeptide, 14 amino acids long, derived from Human NFkB p100 / p52 around the phosphorylation site of Serine 865.

Positive control

WB: extract of ovary cancer cells. IHC: and breast carcinoma tissue.

Properties

Form

Liquid

Storage instructions

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

Storage buffer

Preservative: 0.02% Sodium Azide
Constituents: 50% Glycerol, PBS (without Mg2+ and Ca2+), 150mM Sodium chloride, pH 7.4

Concentration

Concentration information loading...

Purity

Immunogen affinity purified

Purification notes

This antibody was affinity purified from rabbit antiserum by affinity chromatography using epitope specific immunogen.

Clonality

Polyclonal

Isotype

IgG

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - NFkB p100 / p52 antibody (ab31432)Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - NFkB p100 / p52 antibody (ab31432) image (enlarge)

Applications

Show applications key

Our Abpromise guarantee covers the use of ab31432 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application notes

ELISA: 1/20000.
IHC-P: 1/50 - 1/100.
IP: Use at an assay dependent dilution.
WB: 1/500 - 1/1000. Detects bands at 52 and 100kDa.


Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.

Target

Function

NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65.

Involvement in disease

Note=A chromosomal aberration involving NFKB2 is found in a case of B-cell non Hodgkin lymphoma (B-NHL). Translocation t(10;14)(q24;q32) with IGHA1. The resulting oncogene is also called Lyt-10C alpha variant.
Note=A chromosomal aberration involving NFKB2 is found in a cutaneous T-cell leukemia (C-TCL) cell line. This rearrangement produces the p80HT gene which encodes for a truncated 80 kDa protein (p80HT).
Note=In B-cell leukemia (B-CLL) cell line, LB40 and EB308, can be found after heterogeneous chromosomal aberrations, such as internal deletions.

Sequence similarities

Contains 7 ANK repeats.
Contains 1 death domain.
Contains 1 RHD (Rel-like) domain.

Domain

The C-terminus of p100 might be involved in cytoplasmic retention, inhibition of DNA-binding by p52 homodimers, and/or transcription activation.
The glycine-rich region (GRR) appears to be a critical element in the generation of p52.

Post-translational
modifications

While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p52 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.
Subsequent to MAP3K14-dependent serine phosphorylation, p100 polyubiquitination occurs then triggering its proteasome-dependent processing.
Constitutive processing is tightly suppressed by its C-terminal processing inhibitory domain, named PID, which contains the death domain.

Cellular localization

Nucleus. Cytoplasm. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor.

Target information above from: UniProt accessionQ00653 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • DNA binding factor KBF2 antibody
  • H2TF1 antibody
  • Lymphocyte translocation chromosome 10 antibody
  • Lyt10 antibody
  • Oncogene Lyt 10 antibody
  • DNA binding factor KBF2 antibody
  • DNA-binding factor KBF2 antibody
  • H2TF1 antibody
  • Lymphocyte translocation chromosome 10 antibody
  • Lymphocyte translocation chromosome 10 protein antibody
  • Lyt 10 antibody
  • Lyt10 antibody
  • NFKB2 antibody
  • NFKB2_HUMAN antibody
  • Nuclear factor NF kappa B p100 subunit antibody
  • Nuclear factor NF kappa B p52 subunit antibody
  • Nuclear factor NF-kappa-B p52 subunit antibody
  • Nuclear factor of kappa light polypeptide gene enhancer in B cells 2 antibody
  • Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 antibody
  • Oncogene Lyt 10 antibody
  • Oncogene Lyt-10 antibody
  • p49/p100 antibody
see all

Anti-NFkB p100 / p52 antibody images:

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - NFkB p100 / p52 antibody (ab31432)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - NFkB p100 / p52 antibody (ab31432)

Ab31432, at a dilution of 1/50-1/100, staining NFkB p100 / p52 in paraffin embedded human breast carcinoma tissue by Immunohistochemistry.
Left image: Untreated.
Right image: The same antibody preincubated with synthesized peptide.

References for Anti-NFkB p100 / p52 antibody (ab31432)

This product has been referenced in:

  • Alameda JPet al. An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells. Oncogene : (2010). WB; Human.Read more (PubMed: 20838385) »

See 1 publication for this product

Publishing research using ab31432? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"